Live Breaking News & Updates on Nerve Cap

Stay updated with breaking news from Nerve cap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Axogen has positive nerve implant data

Axogen announced positive topline results from a clinical study evaluating its Axoguard Nerve Cap.  ....

Karen Zaderej , Axoguard Nerve , Nerve Cap , Axoguard Nerve Cap ,

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South Korea , United Kingdom , United States , Haroldd Tamayo , Craig Thomajan , Karen Zaderej , Axogen Inc , Axoguard Nerve , Nerve Cap , Axoguard Nerve Cap , Lead Investigator Craig Thomajan , Managing Partner , Austin Foot , Nerve Protector , Private Securities Litigation Reform Act , Middle East , Annual Report , Quarterly Report , Vice President ,

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

South Korea , United States , United Kingdom , Haroldd Tamayo , Axogen Inc , Axoguard Nerve , Nerve Cap , Axoguard Nerve Cap , Nerve Protector , Private Securities Litigation Reform Act , Middle East , Annual Report , Quarterly Report , Vice President ,

Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
Axogen, Inc.February 18, 2021 GMT
ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study. 
Analysis of the REPOSE study’s 15-subject single arm pilot phase demonstrated that subjects experienced a clinically significant reduction in pain from baseline at each of the 3, 6, 9, and 12 month timepoints following surgical excision of the neuroma and placement of Axoguard Nerve Cap® (p 0.0001). Specifically, the study observed a mean reduction in pain of 69 points at 3 months and 80 points at 12 months as measured on the 100-point Visual Analog Scale (VAS). Additionally, subjects experienc ....

United States , United Kingdom , South Korea , Peter Mariani , Craig Thomajan , Karen Zaderej , Exchange Commission , Axogen Inc , Axoguard Nerve Cap , Visual Analog Scale , Physical Function , Sleep Disturbance , Pain Interference , Spain Intensity , Spain Behavior , Peripheral Nerve Surgeon , Austin Foot , Ankle Specialists , Subject Blinded Comparative Study , Symptomatic Neuroma , Recurrent End Neuroma Pain , Nerve Cap , Nerve Graft , Nerve Connector , Nerve Protector , Soft Tissue Membrane ,